Home › Trials › NCT06293950
Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 4 to 14

Using stem cells from Wharton jelly to treat autism

Official title: Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism

Run by University of Jordan · NCT06293950 · Data updated 2026-11-12

This study is testing if stem cells from Wharton jelly can help children with autism improve their social skills and behavior.

Quick facts

PhasePhase 1
Study typeInterventional
Ages4 Years to 14 Years
SexAll
Enrollment14 (estimated)
SponsorUniversity of Jordan
Academic / other
Locations1 site (Amman)
StatusRecruiting
StartedMarch 9, 2022
Main results expectedJune 2026
Study endsDecember 2027
Registry record updatedJanuary 24, 2025
Trial IDNCT06293950 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are children aged 4 to 14 years diagnosed with Autism Spectrum Disorders.

Probably not a fit

Patients over the age of 14, those with severe allergies, or those with a history of significant neurological issues may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of allogeneic Wharton Jelly Mesenchymal Stromal Cells (WJMSC) as a potential treatment for Autism Spectrum Disorders (ASDs). The study aims to enroll 14 participants aged 4 to 14 years who meet the criteria for ASD, focusing on the immunologic properties of stem cells to address the neurobiological changes associated with autism. Participants will receive WJMSC and be monitored for improvements in social communication and behavioral patterns. The trial is designed to assess the safety and efficacy of this innovative approach in a Phase 1 setting.

Why it matters

Potential benefit: If successful, this treatment could provide a novel therapeutic option for children with autism, potentially improving their social communication and behavioral symptoms.

How similar studies have gone: While the use of stem cells in treating autism is a novel approach, preliminary studies in related areas have shown promise, but this specific application remains largely untested.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* 14 subjects, 4-14 years of age, will be enrolled into this study, who meet the criteria for (ASD

Exclusion Criteria:

* Age \> 14 years.
* Patient weighing \< 10 kg.
* History of severe Allergy
* History of severe head trauma, defined by loss of consciousness or hospitalization, skull fracture, or stroke.
* Seizure within the last year before enrollment, or the need for seizure medications either at present or in the past.
* Evidence or history of severe, moderate, or uncontrolled systemic disease.
* Inability to follow the prescribed dosing and follow-up schedule.
* Use of any stimulant or non-stimulant medication or medications given for attention deficit hyperactivity disorder (ADHD) must be discontinued 7 days before the initial randomized study period.
* Subjects taking a selective serotonin reuptake inhibitor (SSRI) must be on a stable dose for a minimum of 30 days before entering the study.
* History of premature birth \<35 weeks' gestation.
* Prior history of stroke in utero or other in utero insult.

Where it's running

  • Cell Therapy Center
    Amman, Jordan     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Autism 558University of Jordan 7
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.